nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—YAP1—head and neck cancer	0.15	0.217	CbGpPWpGaD
Dolutegravir—UGT1A1—Porphyrin metabolism—UROD—head and neck cancer	0.142	0.205	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—head and neck cancer	0.0678	0.0979	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—head and neck cancer	0.0331	0.0477	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—head and neck cancer	0.0282	0.0408	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—head and neck cancer	0.0278	0.0401	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK1—head and neck cancer	0.0269	0.0388	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—head and neck cancer	0.0264	0.0381	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—head and neck cancer	0.0233	0.0337	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—head and neck cancer	0.0216	0.0312	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—head and neck cancer	0.0191	0.0275	CbGpPWpGaD
Dolutegravir—Rash generalised—Docetaxel—head and neck cancer	0.0169	0.0551	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—NAT2—head and neck cancer	0.0158	0.0228	CbGpPWpGaD
Dolutegravir—Prurigo—Docetaxel—head and neck cancer	0.0156	0.0507	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.0152	0.0219	CbGpPWpGaD
Dolutegravir—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.0126	0.041	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.0124	0.018	CbGpPWpGaD
Dolutegravir—Inflammation—Fluorouracil—head and neck cancer	0.0103	0.0335	CcSEcCtD
Dolutegravir—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00943	0.0307	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—NAT2—head and neck cancer	0.00925	0.0134	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—NAT2—head and neck cancer	0.00913	0.0132	CbGpPWpGaD
Dolutegravir—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00907	0.0295	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFA—head and neck cancer	0.00897	0.013	CbGpPWpGaD
Dolutegravir—Neutropenia—Hydroxyurea—head and neck cancer	0.00813	0.0265	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—head and neck cancer	0.00781	0.0113	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00761	0.0248	CcSEcCtD
Dolutegravir—Inflammation—Docetaxel—head and neck cancer	0.00742	0.0242	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00733	0.0239	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.00686	0.0099	CbGpPWpGaD
Dolutegravir—Vertigo—Vinblastine—head and neck cancer	0.00597	0.0194	CcSEcCtD
Dolutegravir—Renal impairment—Docetaxel—head and neck cancer	0.00549	0.0179	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.00525	0.00757	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—head and neck cancer	0.00521	0.00752	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00512	0.0167	CcSEcCtD
Dolutegravir—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00485	0.0158	CcSEcCtD
Dolutegravir—Skin disorder—Hydroxyurea—head and neck cancer	0.0048	0.0156	CcSEcCtD
Dolutegravir—Abdominal pain upper—Docetaxel—head and neck cancer	0.00477	0.0155	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00461	0.015	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—head and neck cancer	0.00457	0.0066	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—head and neck cancer	0.00451	0.00651	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00443	0.0144	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—head and neck cancer	0.00433	0.00626	CbGpPWpGaD
Dolutegravir—Abdominal pain—Vinblastine—head and neck cancer	0.00429	0.0139	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00427	0.00617	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00427	0.0139	CcSEcCtD
Dolutegravir—Fatigue—Hydroxyurea—head and neck cancer	0.00426	0.0139	CcSEcCtD
Dolutegravir—Neutropenia—Docetaxel—head and neck cancer	0.00422	0.0137	CcSEcCtD
Dolutegravir—Hypersensitivity—Vinblastine—head and neck cancer	0.004	0.013	CcSEcCtD
Dolutegravir—Renal failure—Docetaxel—head and neck cancer	0.00396	0.0129	CcSEcCtD
Dolutegravir—Asthenia—Vinblastine—head and neck cancer	0.00389	0.0127	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—UROD—head and neck cancer	0.00381	0.0055	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00381	0.0124	CcSEcCtD
Dolutegravir—Diarrhoea—Vinblastine—head and neck cancer	0.00371	0.0121	CcSEcCtD
Dolutegravir—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00364	0.0119	CcSEcCtD
Dolutegravir—Hepatitis—Docetaxel—head and neck cancer	0.00362	0.0118	CcSEcCtD
Dolutegravir—Dizziness—Vinblastine—head and neck cancer	0.00359	0.0117	CcSEcCtD
Dolutegravir—Urinary tract disorder—Docetaxel—head and neck cancer	0.00357	0.0116	CcSEcCtD
Dolutegravir—Asthenia—Hydroxyurea—head and neck cancer	0.00355	0.0115	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—head and neck cancer	0.00355	0.0115	CcSEcCtD
Dolutegravir—Nervous system disorder—Fluorouracil—head and neck cancer	0.00349	0.0114	CcSEcCtD
Dolutegravir—Vomiting—Vinblastine—head and neck cancer	0.00345	0.0112	CcSEcCtD
Dolutegravir—Headache—Vinblastine—head and neck cancer	0.0034	0.0111	CcSEcCtD
Dolutegravir—Diarrhoea—Hydroxyurea—head and neck cancer	0.00338	0.011	CcSEcCtD
Dolutegravir—Dizziness—Hydroxyurea—head and neck cancer	0.00327	0.0106	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—head and neck cancer	0.00327	0.0106	CcSEcCtD
Dolutegravir—Nausea—Vinblastine—head and neck cancer	0.00322	0.0105	CcSEcCtD
Dolutegravir—Insomnia—Fluorouracil—head and neck cancer	0.00322	0.0105	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—head and neck cancer	0.00317	0.0103	CcSEcCtD
Dolutegravir—Vomiting—Hydroxyurea—head and neck cancer	0.00314	0.0102	CcSEcCtD
Dolutegravir—Rash—Hydroxyurea—head and neck cancer	0.00312	0.0101	CcSEcCtD
Dolutegravir—Dermatitis—Hydroxyurea—head and neck cancer	0.00312	0.0101	CcSEcCtD
Dolutegravir—Headache—Hydroxyurea—head and neck cancer	0.0031	0.0101	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00307	0.01	CcSEcCtD
Dolutegravir—Nausea—Hydroxyurea—head and neck cancer	0.00294	0.00956	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00266	0.00866	CcSEcCtD
Dolutegravir—Hypersensitivity—Fluorouracil—head and neck cancer	0.00262	0.00853	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—head and neck cancer	0.00252	0.0082	CcSEcCtD
Dolutegravir—Pruritus—Fluorouracil—head and neck cancer	0.00252	0.00819	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—head and neck cancer	0.0025	0.00812	CcSEcCtD
Dolutegravir—Diarrhoea—Fluorouracil—head and neck cancer	0.00244	0.00792	CcSEcCtD
Dolutegravir—Dizziness—Fluorouracil—head and neck cancer	0.00235	0.00766	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—head and neck cancer	0.00232	0.00756	CcSEcCtD
Dolutegravir—Vomiting—Fluorouracil—head and neck cancer	0.00226	0.00736	CcSEcCtD
Dolutegravir—Rash—Fluorouracil—head and neck cancer	0.00224	0.0073	CcSEcCtD
Dolutegravir—Dermatitis—Fluorouracil—head and neck cancer	0.00224	0.0073	CcSEcCtD
Dolutegravir—Headache—Fluorouracil—head and neck cancer	0.00223	0.00726	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00222	0.00722	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—head and neck cancer	0.00222	0.00721	CcSEcCtD
Dolutegravir—Nausea—Fluorouracil—head and neck cancer	0.00211	0.00688	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—head and neck cancer	0.0021	0.00684	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—head and neck cancer	0.00203	0.00661	CcSEcCtD
Dolutegravir—Hypersensitivity—Docetaxel—head and neck cancer	0.00189	0.00616	CcSEcCtD
Dolutegravir—Asthenia—Docetaxel—head and neck cancer	0.00184	0.006	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—head and neck cancer	0.00182	0.00591	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—head and neck cancer	0.00176	0.00572	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—head and neck cancer	0.0017	0.00553	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—head and neck cancer	0.00163	0.00531	CcSEcCtD
Dolutegravir—Rash—Docetaxel—head and neck cancer	0.00162	0.00527	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—head and neck cancer	0.00162	0.00527	CcSEcCtD
Dolutegravir—Headache—Docetaxel—head and neck cancer	0.00161	0.00524	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—NAT2—head and neck cancer	0.00158	0.00228	CbGpPWpGaD
Dolutegravir—Nausea—Docetaxel—head and neck cancer	0.00153	0.00497	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—DPYD—head and neck cancer	0.00139	0.002	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—YAP1—head and neck cancer	0.00132	0.0019	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—head and neck cancer	0.000791	0.00114	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—head and neck cancer	0.000782	0.00113	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GPX1—head and neck cancer	0.000748	0.00108	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—head and neck cancer	0.000741	0.00107	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—head and neck cancer	0.000441	0.000636	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—head and neck cancer	0.000384	0.000555	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—head and neck cancer	0.000271	0.000391	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—head and neck cancer	0.000221	0.00032	CbGpPWpGaD
